<DOC>
	<DOCNO>NCT00306748</DOCNO>
	<brief_summary>The purpose study determine safety gastrointestinal pharmacodynamics ( stool frequency , stool consistency , stool ease passage , stool completeness evacuation ) MD-1100 acetate administer daily 14 day .</brief_summary>
	<brief_title>Phase 2 Study MD-1100 Acetate Administered 14 Days Patients Meeting Criteria Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Male nonpregnant , nonbreastfeeding female , age 1870 year old time first dose ; Sexually active patient childbearing potential agree use doublebarrier birth control ; Females childbearing potential must complete negative pregnancy test prior first dose ; Negative colonoscopy within 10 year completion negative flexible sigmoidoscopy age 50 provide history rectal bleeding , weight loss , anemia ; BMI must great than/equal 18.5 less 35.0 ; Successful completion physical exam , 12lead ECG , clinical laboratory test prior first dose study medication ; Vital sign must clinicallysignificant finding within 4 hour first dose study medication ; Patient report 3 less spontaneous bowel movement ( SBMs ) per week meet 1 follow criterion constipation 12 week previous 12 month : strain least 25 % bowel movement ( BMs ) , lumpy hard stool least 25 % BMs , sensation incomplete evacuation least 25 % BMs ; Patient report 3 less SBMs 7day Pretreatment Period ; Patient compliant IVRS least 6 day 7day Pretreatment Period . Use investigational drug within 30 day ; Laxative/enemainduced diarrhea within 60 day ; Patient meet ROME II criterion functional diarrhea ; Most bothersome symptom moderate severe abdominal pain abdominal discomfort ; History cancer , inflammatory bowel disease , ischemic colitis , bowel resection , colostomy , fecal impaction ; Diagnosis cathartic colon laxative/enema abuse , pelvic floor dysfunction , evacuation disorder , bulimia , anorexia , neurological disorder ; Surgery within 30 day GI surgery within 6 month first dose study medication . Cholecystectomy and/or appendectomy acceptable complete 60 day prior first dose study medication ; Patient may use disallowed medication ( prescription and/or overthecounter treatment chronic constipation CIBS , drug target 5HT4 , 5HT2b , 5HT3 receptor , narcotic , anticholinergic agent , GI preparation , etc . ) 7day Pretreatment Period study . Stable , continuous ( 30 day ) use dietary fiber acceptable . Any acute chronic condition would limit patient 's ability complete and/or participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Chronic Constipation</keyword>
	<keyword>Chronic Idiopathic Constipation</keyword>
	<keyword>Constipation</keyword>
	<keyword>CIC</keyword>
	<keyword>CC</keyword>
	<keyword>MD-1100</keyword>
	<keyword>MD-1100 Acetate</keyword>
	<keyword>Microbia</keyword>
	<keyword>Microbia , Inc .</keyword>
	<keyword>linaclotide</keyword>
	<keyword>linaclotide acetate</keyword>
</DOC>